INTERNATIONAL PREVALENCE OF CONSULTATION WITH A NATUROPATHIC PRACTITIONER: A SYSTEMATIC REVIEW AND META-ANALYSIS

Authors:

Steel, Amie¹

Redmond, Rebecca¹

Schloss, Janet^{1,3}

Cramer, Holger^{1,2,3P2}

Goldenberg, Joshua^{1,4}

Leach, Matthew^{1,3}

Harnett, Joanna^{1,5}

Van de Venter, Claudine¹

McLintock, Andy¹

Bradley, Ryan^{1,3,4,6}

Hawrelak, Jason^{1,7}

Cooley, Kieran^{1,8}

Leung, Brenda^{1,9}

Adams, Jon¹

Corresponding author:

Dr Amie Steel

Wardle, Jon^{1,3}

Amie.steel@uts.edu.au

¹University of Technology Sydney, Faculty of Health, Australian Research Centre in Complementary and Integrative Medicine, Ultimo NSW Australia

²Department of Internal and Integrative Medicine, Evang. Kliniken Essen-Mitte, Faculty of Medicine, University of Duisburg-Essen, Germany

³Southern Cross University, National Centre for Naturopathic Medicine, Lismore, Australia

⁴Helfgott Research Institute, National University of Natural Medicine, Portland, OR, USA

⁵Faculty of Medicine and Health, Sydney Pharmacy School, The University of Sydney, Sydney, Australia

⁶Herbert Wertheim School of Public Health and Human Longevity Science, University of California, San Diego, La Jolla, CA, USA

⁷ College of Health and Medicine, University of Tasmania, Hobart, TAS, Australia

⁸Canadian College of Naturopathic Medicine, Toronto, ON, Canada

⁹Faculty of Health Sciences, University of Lethbridge, Lethbridge, AB, Canada

ABSTRACT (300 words)

Objectives: Naturopathy is a traditional medicine system informed by codified philosophies and principles, and an emphasis on non-pharmacologic therapeutic interventions. While naturopathy is practiced by approximately 75 000 to 100 000 naturopathic practitioners in at least 98 countries, little is known about the international prevalence of history of consultation with a naturopathic practitioner. This study reports a systematic review and meta-analysis of studies describing the global prevalence of history of consultation with a naturopathic practitioner by the general population.

Setting: The included literature was identified through a systematic search of eight databases between September and October 2019, as well as the grey literature.

Participants: Studies were included if they reported the prevalence rate of consultations with a naturopathic practitioner by the general population

Interventions: Survey items needed to report consultations with a naturopathic practitioner as defined in the country where data was collected, and not combine naturopathic consultations with other health services or only report consulations for illness populations.

Primary and secondary outcome measures: Primary measures used for the analysis was consultations in the previous 12-months. Other prevalence timeframes were reported as secondary measures.

Methods: Meta-analysis of prevalence data was conducted using random effects models based on individual countries and World Health Organisation (WHO) world regions.

Results: The literature search identified eight manuscripts summarizing 13 studies reporting prevalence for inclusion in the review. All included studies had a low risk of bias. Meta-analysis of the included studies by world region found the 12-month prevalence of history of naturopathy consultations ranged from 1% in the Region of the Americas to 6% in the European and Western Pacific Regions.

Conclusions: There are up to 6-fold differences in the prevalence of naturopathy consults over 12-months between and within world regions, which may be driven by a range of policy, legislative and social factors.

STRENGTHS AND LIMITATIONS OF THIS STUDY

- Naturopathy is one of the most commonly used traditional and complementary medicines in the Western
 world and this is the first systematic review and meta-analysis reporting the prevalence of consutations
 with a naturopathic practitioner.
- This study includes only includes data published after 2010 to ensure the results are contemporary, however this may have excluded some studies in countries with older data.
- The results are limited by the poor availability of data reporting consultations with a naturopathic practitioner, including in countries where a large number of naturopathic practitioners are known to provide care.

INTRODUCTION

Naturopathy is a traditional medicine system underpinned by six philosophical principles (see Table 1), which were codified by the profession in the 20th century [1]. These philosophical principles characterize naturopathic practice and are globally accepted by the profession [2]. Other defining tenets of naturopathic practice are patient-centeredness and individualization, with naturopaths typically drawing upon a range of therapeutic interventions (e.g., diet and lifestyle counselling, herbal medicine, nutritional supplementation, manual therapies, and mind-body practices) to best meet the health care needs and preferences of the patient [3]. Globally, naturopathy is practiced in at least 98 countries with representation in every world region [4]. Naturopathy is practiced widely in Europe (n=54 practicing countries), followed by Latin America (n=51), Africa (n=47), and the Western Pacific (n=37) [5]. Estimates from the World Naturopathic Federation suggest there are between 75,000 and 100,000 naturopaths currently in clinical practice across the world [5].

Training of the naturopathic workforce is currently provided by an estimated 90 education institutions globally, with entry-level qualifications ranging from technical diploma to clinical doctorate [3]. The curriculum of these naturopathic programs typically includes content in health sciences (e.g., anatomy, physiology, chemistry, and biochemistry), clinical sciences (e.g. clinical examination, differential diagnosis), social sciences (e.g. psychology, counselling), and naturopathic sciences (e.g. nutritional medicine, herbal medicine, lifestyle medicine, dietary modification, homeopathy, and manual therapies) [4]. Despite similarities in the content of these training programs, naturopathic scope of practice varies considerably across jurisdictions due to differences in regulation and legislative requirements [6].

In response to an increase in the use of traditional and complementary medicine (including the utilization of naturopathic health services), the World Health Organisation has developed global strategies to ensure access to safe and effective healthcare, which include promoting the integration of traditional and complementary therapies (including naturopathy) into healthcare systems [7]. Several international research studies suggest the demand for naturopathic services may be attributed to personal healthcare beliefs, dissatisfaction with biomedical care, increased disease severity, and unmet healthcare needs [8-15]. Nevertheless, the global use of naturopathic services is not well understood. Therefore the aim of this study was to describe the prevalance of a history of consultations with naturopathic practitioners globally, including potential differences across world regions.

METHODS

ΑΙΜ

This study aims to describe the global prevalence of a history of consultation with a naturopathic practitioner by the general population.

STUDY DESIGN

A systematic review and meta-analysis of prevalence studies were undertaken in accordance with the AMSTAR 2 guidelines [16]. The protocol for this review was submitted to PROSPERO on the 2nd September, 2019 and was registered on the 28th April, 2020 [CRD42020145529].

INCLUSION AND EXCLUSION CRITERIA

Articles were included that reported original data from cohort studies, cross-sectional studies, survey research, case-control studies, prevalence studies, or epidemiologic studies. Studies reporting on the general population prevalence of consultations with a naturopathic practitioner either in the previous 12 months or over the user's lifetime were considered for inclusion. All relevant papers were included irrespective of language of publication or risk of bias score. Articles were excluded that presented results from specific sub-patient populations (e.g. children, female or male specific, age limitations, illness populations). Studies were also excluded if they only presented the prevalence of consultations with other health professionals that may use treatments commonly associated with naturopathy (e.g. herbal medicine, hydrotherapy, yoga, etc) but were not explicitly named as naturopathic practitioners, or where naturopathic consultation rates were conflated with a cumulative group of health services (such as complementary and alternative medicine [CAM]). To ensure the analysis reflected contemporary patterns of use, studies were excluded if they were published before 2010.

SEARCH STRATEGY

A systematic electronic search of the following databases was conducted between 6th September and 2nd October 2019: MEDLINE, AMED, EMBASE, CINAHL, Global Health, WHO Iris, PROQUEST dissertations database, and Lilac. The complete search strategy for MEDLINE is presented in Table 2. A search for grey literature was also performed. The search targeted countries where, according to the WHO Global Report on Traditional and Complementary Medicine (2019) [20], naturopathic practitioners provide care to the community. The search was performed using the Google search engine and the terms *prevalence*, *use*, *naturopathy*, *report*, and the country name.

ARTICLE IDENTIFICATION AND SELECTION

A list of all citations identified through the search were exported from each database by AM and uploaded to Covidence [17] for filtering and selection. Initial screening of title and abstracts against the inclusion/exclusion criteria was conducted by AM. Two members of the authorship team (AM and AS) then independently reviewed the full text of the remaining citations to determine their suitability against the same criteria. Any differences were resolved through discussion between both reviewing authors. The list of bibliographic references and subsequent citations (identified through Google Scholar) of included papers were also checked by AS to identify additional articles otherwise missed through the database search. JHar and JS extracted data from the included papers. AS and JS assessed the papers for quality of reporting against the STROBE checklist [18]; risk of bias was assessed using the tool developed by Hoy et al [19] by JG and JAH. Differences in scoring for both tools were resolved through discussion until consensus was achieved.

ANALYSIS

The results were grouped for narrative presentation of results in accordance with the World Health Organisation (WHO) world regions [21]. Where studies reported the results of more than one year, these were treated as different studies in the analysis. Articles with unclear numerators or denominators were calculated by the research team where the necessary information was provided or checked against source documents for the same study. Authors were contacted to verify information not able to be determined through these other methods.

Prevalence rates and standard errors were calculated using a standardized Microsoft Excel (version 12.3.5, Microsoft, Redmond, USA) spreadsheet [22]. Review Manager software (version 5.3, Nordic Cochrane Centre, Copenhagen, Denmark) was used to conduct the meta-analysis, using random effects models by the Generic Inverse Variance method. Weighted prevalence rates with 95% confidence intervals (95% CI) were calculated for 12-month prevalence and lifetime prevalence separately. Separate analyses were conducted for a) country of origin and b) WHO world regions.

Heterogeneity between studies was estimated on the basis of the raw proportions, by using the I^2 statistic. Intervals were defined as per published guidance [23, 24]: low heterogeneity (I^2 of 0–24%); moderate heterogeneity (I^2 of 25–49%); substantial heterogeneity (I^2 of 50–74%); relevant heterogeneity (I^2 of 75–100%). In order to assess heterogeneity, χ^2 tests were conducted with p \leq 0.10 [24]. We intended to perform sensitivity analyses to compare differences between outcomes on all studies to studies with low risk of bias only (defined as <4 items recorded as 'no' on the Hoy et al tool). However, as all studies were classified as low risk of bias, this was not possible.

ETHICS APPROVAL

As this study presents a review and synthesis of published research and does not engage with data collection of human or animal subjects, it is deemed negligible risk and no ethics approval was required.

RESULTS

SEARCH CHARACTERISTICS

The article selection process is presented in Figure 1. The database search identified 13,968 citations including 2,509 duplicates. Of these, 11,374 were excluded through title and abstract screening. The full text of the remaining 85 articles were assessed for eligibility, of which 78 were excluded for the following reasons: not reporting naturopathic consultations (n=54), conference abstract only (n=9), not original research (n=7), wrong outcomes reported (n=5), overlooked duplicate (n=2), and wrong study design (n=1) (full list of excluded studies available in Supplementary File 1). This resulted in seven articles being retained. A search for grey literature using the Google search engine was also performed, and targeted countries where, according to the WHO Global Report on Traditional and Complementary Medicine (2019) [6], naturopaths/naturopathic doctors are providing care to the community. The reference lists and subsequent citations of the remaining articles were checked and when combined with the results of the Google Search, resulted in identification of an

additional 19 articles (3 references and 16 citations), of which one report was found to meet the inclusion criteria for this review. This yielded a total of eight included studies, one of which was published in a report.

STUDY CHARACTERISTICS

The included studies reporting 12-month prevalence of naturopathy use in a national population were represented across four of the six WHO world regions: European (n=2) [25, 26], Eastern Mediterranean (n=1) [27], Region of the Americas (n=3) [28-30], and the Western Pacific (n=1) [31] (see Table 3). One of the studies from Canada presented the lifetime prevalence of naturopathy use [30], and an additional study from India (South East Asian World region) did not specify the time period during which naturopathy was used [21] (see Table 4).

All included studies sampled the general adult population and reported data from a nationally representative sample or demonstrated a distribution of economic categories, except for one study from Israel whereby the majority of participants' subjective economic status was rated as 'very good' or 'good' [27]. Four studies included prevalence data from more than one time point [26-28, 30], with the earliest data collected in 1993 [27]. Two papers reported data from the same national cohort study, but from different time points [28, 29]. All studies included participants from both urban and rural locations.

RISK OF BIAS

Critical appraisal of the included studies is presented in Table 5. All studies were determined to have a low risk of bias, except for one study that was suspected of having non-response bias [27]. All but one study [31] had problematic reporting of the numerator and denominator, however, this was able to be addressed by the research team by interrogating the provided data or checking source documents from the primary cohort studies. One study was identified as not having an acceptable case definition [21] as it did not specify the period of time covering naturopathy use (e.g. previous 12 months or users' lifetime).

Assessent of the reporting quality of included studies identified several issues. More than one-half of studies did not clearly identify the study design in the title [21, 27-31]. None of the included studies provided reasons for non-participation or provided information about missing data. Four of the included studies did not acknowledge the limitations of their research. In one case, some of the omissions in reporting may be explained by the nature of the publication (i.e. grey-literature report rather than a peer-reviewed journal article) [30].

SUMMARY OF FINDINGS

The 12-month prevalence reported in studies from the European region ranged between 2% in the UK [25] to 7.7% in Switzerland [26]. One study from the Eastern Mediterranean region (i.e. Israel) [27] reported multiple prevalence rates ranging from 20% in 1993 through to 18% in 2007. Three studies from the Region of the Americas reported 12-month prevalence rates of naturopathy use between 3% (in 1997) and 5% (in 2016) in Canada [30], and between 0.25% (in 2002) and 0.4% (in 2015) in the United States [28, 29]. One study from the Western Pacific region (i.e. Australia) reported a 6.2% prevalence rate [31].

Two studies reported prevalence of naturopathy use over other time periods. One study from the Region of the Americas (Canada) indicated 6% of the general population in 1997, 9% in 2006, and 11% in 2016 used naturopathy at some point in the user's lifetime [30]. A study from the South-East Asian world region indicated 10% of the population had used naturopathy and yoga, but the timeframe of use was not specified [21].

META-ANALYSIS RESULTS

The estimated 12-month prevalence rates of naturopathy use for different countries are shown in Figure 2. Prevalence rates significantly differed between countries (p<0.001) and ranged from less than 1% of the population in the USA to 8% in Switzerland. While the primary studies were subject to wide heterogeneity, significant heterogeneity was only found for Canada (p=0.01) and the USA (p<0.001).

Regarding WHO world regions, 12-month prevalence of naturopathy use ranged from 1% in the Region of the Americas to 6% in European and Western Pacific Regions, again with significant differences between regions (p<0.001; Figure 3). Relevant and statistically significant heterogeneity was present in studies involving the European Region (p<0.001), and Region of the Americas (p<0.001).

Since all studies were classified as having low risk of bias, no sensitivity analyses were conducted. No metaanalysis could be performed on studies reporting prevalence of naturopathy use over other time periods due to the paucity and heterogeneity of studies reporting this outcome.

DISCUSSION

This review presents the most recent synthesis of evidence of the global prevalence of consultations with naturopaths/naturopathic doctors. The prevalence of naturopathy/naturopathic medicine use was reported in seven countries, across five WHO designated regions of the world. Of the regions reporting 12-month prevalence rates, the highest was in the Eastern Mediterranean region (Israel), with 18% (2007) to 20% (1993) of the general population seeking the services of a naturopath/naturopathic doctor. The lowest reported 12-month prevalence of naturopathy use was observed in the Americas (USA), with a rate of 0.4% (2012). Lifetime prevalence of use was reported in two countries: Canada (6% in 1997 to 11% in 2016); and India (7% rural, 12% urban in 2011/12). Where more than one timeframe of data was available, there was a relative amount of consistency across time suggesting naturopathy/naturopathic medicine use is temporally stable in these countries.

The wide range in the rates of consultation with a naturopath/naturopathic doctor may reflect differences in the perception and availability of naturopathy in specific countries. For example, while national prevalence of consultations with naturopaths in the USA is relatively low, this may obscure significant heterogeneity within that region. For example, insurance data from Washington state shows prevalence of naturopathic consultation to be four times higher than the national prevalence (1.6% v 0.4%) [32]. Such heterogeneity may be similarly observed in other regions and may be due to several factors. In the USA recognition of the naturopathic profession through licensure is not uniformly applied across that nation [33], and distribution of the naturopathic workforce has historically been determined by the proximity to naturopathic educational

institutions [34]. Insurance coverage is also known to be a significant driver of naturopathic use [32], and variable insurance coverage arrangements for naturopathy – as observed in the USA [35] – may also result in regional differences. Further attention towards regional variations and heterogeneity, particularly as it relates to specific barriers and facilitators to appropriate utilization of naturopathic services - is warranted.

The wide range in rates of naturopathy use may also reflect differences in scope of practice in each world region. For example, in the USA, naturopathic physicians are considered to bridge conventional medicine and CAM modalities [36], while in Germany, naturopathic practitioners known as "Heilpraktiker" are a distinct category and reportedly have inconsistent training and clinical abilities [37]. As such, the term naturopathy may be differentially classifying practitioners due to professionalization, resulting in an underestimate of use in some countries and overestimate in others. Further consideration of the implications associated with the inconsistent 'protection' of professional titles and defined scopes of practice for naturopaths/naturopathic doctors by country is likely to influence the prevalence of use by the public [2].

Prevalence data from some countries may also be impacted by definitional difficulties or confusion around the term 'naturopathy'. For example, naturopathy is often grouped under a broader nomenclature as one of the many modalities or therapies considered 'complementary approaches to healthcare' [38] or "integrative medicine" and thus may not be individually represented in the publications included in our analysis. Multiple practitioner types may also present difficulties for data collection. For example, a review of CAM services in Europe, of the (22,300) practitioners of naturopathy, 15,000 were identified as (mostly German) medical doctors [39]. Thus, patients may not identify obtaining naturopathy as a service per se, but as part of the standard care they receive from a medical doctor who integrates naturopathic principles or modalities into their practice. This may be one reason why three of the largest European countries by naturopathic workforce (Germany, Portugal and Spain [2]) were not represented in this review. Thus, the true prevalence of naturopathic consultations is likely under-reported. Further, an examination of government administered national health surveys of the general population in the countries represented by WNF member organisations, found only Switzerland, Northern Ireland, USA, Mexico and India currently included items that specifically measured consultations with a naturopath/naturopathic doctor (see Supplementary File 2). To evaluate the potential role of naturopaths in care delivery, it is imperative that naturopathic health services and workforce research data is captured in all countries where there is a significant naturopathic presence.

Furthermore, although naturopathic practice is relatively consistent globally, local, and regional variations in preferred therapies may result in point-of-service differences that may impact prevalence of naturopathic consultations in those countries. For example, in the United Kingdom, historical connections between osteopathy and naturopathy may drive naturopathic use for musculoskeletal conditions in that country more than in countries like Australia, where naturopathy and herbalism have had a larger shared history and connection [40]. Some studies in this review explicitly combined queries about naturopathic utilization with other CAM practices — for example, herbalism and naturopathy in the Australian study. Thus, it is important

that a reliable validated instrument is developed for collecting more specific data about naturopathic service utilization within and across countries to establish 'true' prevalence of use information.

While prevalence data provides a snapshot of a given populations' use of naturopathy, less is known about the factors associated with that use. For example, factors that have previously been raised as impacting the use of naturopathy/naturopathic medicine, include licensure and regulation, scope of practice, training of new students and therefore number of naturopaths/naturopathic doctors in the workforce, or country specific health systems that influence the support and reimbursements of naturopathic services (e.g. insurance vs out of pocket) [41]. By focusing on general population utilization, this study may also not reflect differences in prevalence of use for different clinical conditions. For example, Australian studies published before 2010 show a self-reported prevalence of naturopathic use among the general population of mid-aged women to be 8.7%, while rates for cancer (15.7%) and depression (22.2%) were significantly higher [9]. Similar variations were seen in insurance data from Washington state in the US, where 7.1% of insured cancer patients made claims for naturopathic treatment, compared to 1.6% of general enrollees [32].

One of the limitations of prevalence studies in the context of naturopathy, is they fail to capture the breadth of treatments that is unique to naturopathy and they do not capture data associated with the quality of care, role within healthcare systems, nor the efficacy and safety of naturopathic approaches to the management of specific conditions [42]. Thus, research into the quality, safety, efficacy, and cost effectiveness of naturopathy/naturopathic medicine would provide pragmatic understanding about the contribution of naturopathy to healthcare within populations and more broadly across the world. Additionally, although limiting data collection to studies published after 2010 helps to ensure prevalence data most accurately reflects contemporary utilization, such time limits may have excluded some studies in regions that were missing from the review. Additionally, observing changes in prevalence of naturopathic consultations over time may also be able to offer insights into the changing role of naturopathy/naturopathic medicine in relation to health systems changes or generational health needs [43].

Conclusion

Although the naturopathic workforce has a significant presence globally, there is limited detailed data on the prevalence of naturopathic consultations. As such, there is a need for a reliable validated instrument to be developed for collecting more specific data about naturopathic service utilization within and across countries. Nevertheless, current evidence reports a 12-month prevalence of naturopathy use ranging from 1% in the Region of the Americas to 6% in European and Western Pacific Regions, though there are significant differences between and within world regions. Differences in naturopathic utilization in these regions may be indicative of a range of policy, legislative and social factors impacting the naturopathic profession. Despite these ongoing factors, further research attention is warranted to support the integration of naturopathic services into healthcare systems to ensure consumers have access to safe and effective multi-disciplinary care.

References

- 1. Snider, P. and J. Zeff, *Unifying Principles of Naturopathic Medicine Origins and Definitions*. Integrative Medicine: A Clinician's Journal, 2019. **18**(4): p. 36.
- World Naturopathic Federation Roots Committee, WNF Naturopathic Roots Report. 2016, World Naturopathic Federation,: Toronto, Canada.
- 3. Dunn, J., et al., Characteristics of global naturopathic education, regulation, and practice frameworks: results from an international survey. BMC complementary medicine and therapies, 2021. **21**(1): p. 1-19.
- 4. Steel, A., et al., Overview of international naturopathic practice and patient characteristics: results from a cross-sectional study in 14 countries. BMC Complementary Medicine and Therapies, 2020. **20**(1): p. 59.
- 5. World Naturopathic Federation, 2016 Naturopathic Numbers Report. 2016, World Naturopathic Federation: Canada.
- 6. World Naturopathic Federation, *Global Naturopathic Regulation*. 2018, World Naturopathic Federation: Toronto, Ontario.
- 7. Smith, M., A. Burton, and T. Falkenberg, World Health Organization Traditional Medicine Strategy 2014–2023. New strategy for traditional and complementary medicine includes the development and use of herbal medicinal preparations. HerbalEGram, 2014. 11(5).
- 8. Leach, M.J., Profile of the complementary and alternative medicine workforce across Australia, New Zealand, Canada, United States and United Kingdom. Complementary therapies in medicine, 2013. **21**(4): p. 364-378.
- 9. Reid, R., et al., Complementary medicine use by the Australian population: a critical mixed studies systematic review of utilisation, perceptions and factors associated with use. BMC Complementary and Alternative Medicine, 2016. **16**(1): p. 176.
- 10. Leach, M.J., Determinants of Complementary Medicine Service Utilization in a Regional South Australian Population: A Cross-Sectional Study. The Journal of Rural Health, 2021. 37(1): p. 69-80.
- 11. Bradley, R., et al., Survey of CAM interest, self-care, and satisfaction with health care for type 2 diabetes at group health cooperative. BMC complementary and alternative medicine, 2011. 11(1): p. 121.
- 12. Foley, H. and A. Steel, *Patient perceptions of clinical care in complementary medicine: A systematic review of the consultation experience.* Patient Educ Couns, 2016. **100**: p. 212-23.
- 13. Foley, H., A. Steel, and J. Adams, *Perceptions of Person-Centred Care Amongst Individuals with Chronic Conditions who Consult Complementary Medicine Practitioners.* Complementary Therapies in Medicine, 2020: p. 102518.
- 14. Foley, H., A. Steel, and J. Adams, Consultation with complementary medicine practitioners by individuals with chronic conditions: Characteristics and reasons for consultation in Australian clinical settings. Health & social care in the community, 2020.
- 15. Legenne, M., et al., Perception of naturopathy for female patients with metastatic gynecological cancer: A qualitative study. Palliative & supportive care, 2015. **13**(6): p. 1663-1668.
- 16. Shea, B.J., et al., AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both. bmj, 2017. **358**.
- 17. Innovation, V.H., Covidence systematic review software. Melbourne, Australia.
- 18. Knottnerus, A. and P. Tugwell, *STROBE--a checklist to Strengthen the Reporting of Observational Studies in Epidemiology*. Journal of clinical epidemiology, 2008. **61**(4): p. 323.
- 19. Hsu, C., et al., New perspectives on patient expectations of treatment outcomes: results from qualitative interviews with patients seeking complementary and alternative medicine treatments for chronic low back pain. BMC Complementary Alternative Medicine, 2014. **14**(1): p. 276.
- 20. Organization, W.H., WHO global report on traditional and complementary medicine 2019, in WHO global report on traditional and complementary medicine 2019. 2019.
- 21. Srinivasan, R. and V.R. Sugumar, *Spread of traditional medicines in India: Results of national sample survey organization's perception survey on use of Ayush.* Journal of evidence-based complementary & alternative medicine, 2017. **22**(2): p. 194-204.

- 22. Neyeloff, J.L., S.C. Fuchs, and L.B. Moreira, *Meta-analyses and Forest plots using a microsoft excel spreadsheet: step-by-step guide focusing on descriptive data analysis.* BMC research notes, 2012. **5**(1): p. 1-6.
- 23. Higgins, J.P., et al., Measuring inconsistency in meta-analyses. Bmj, 2003. 327(7414): p. 557-560.
- 24. Higgins, J.P., et al., Cochrane handbook for systematic reviews of interventions. 2019: John Wiley & Sons.
- 25. Hunt, K.J., et al., *Complementary and alternative medicine use in England: Results from a national survey.* International Journal of Clinical Practice, 2010. **64**(11): p. 1496-1502.
- 26. Klein, S.D., et al., Usage of complementary medicine in Switzerland: Results of the Swiss health survey 2012 and development since 2007. PLoS ONE, 2015. **10**(10): p. no pagination.
- 27. Shmueli, A., I. Igudin, and J. Shuval, *Change and stability: use of complementary and alternative medicine in Israel: 1993, 2000 and 2007.* European Journal of Public Health, 2011. **21**(2): p. 254-259.
- 28. Su, D. and L. Li, *Trends in the use of complementary and alternative medicine in the United States:* 2002-2007. Journal of Health Care for the Poor and Underserved, 2011. **22**(1): p. 296-310.
- 29. Clarke, T.C., et al., Trends in the use of complementary health approaches among adults: United States, 2002-2012. National health statistics reports, 2015(79): p. 1-16.
- 30. Esmail, N., Complementary and Alternative Medicine. 2017: Fraser Institute.
- 31. McIntyre, E., et al., Consultations with Naturopaths and Western Herbalists: Prevalence of Use and Characteristics of Users in Australia. The Journal of Alternative Complementary Medicine, 2019. **25**(2).
- 32. Lafferty, W.E., et al., The use of complementary and alternative medical providers by insured cancer patients in Washington State. Cancer, 2004. **100**(7): p. 1522-30.
- 33. Fleming, S.A. and N.C. Gutknecht, *Naturopathy and the primary care practice*. Primary Care: Clinics in Office Practice, 2010. **37**(1): p. 119-136.
- 34. Albert, D.P. and F.B. Butar, *Distribution, concentration, and health care implications of naturopathic physicians in the United States*. Complementary health practice review, 2004. **9**(2): p. 103-117.
- 35. Whedon, J., et al., *Insurance reimbursement for complementary healthcare services*. The Journal of Alternative and Complementary Medicine, 2017. **23**(4): p. 264-267.
- 36. Litchy, A.P., *Naturopathic physicians: holistic primary care and integrative medicine specialists.* Journal of dietary supplements, 2011. **8**(4): p. 369-377.
- 37. Heudorf, U., A. Carstens, and M. Exner, *Naturopathic practitioners and the public health system. Legal principles as well as experience from naturopathic practitioner candidate tests and hygiene inspections of naturopathic practitioner's practices in the Rhine-Main area in 2004-2007.*Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz, 2010. **53**(2): p. 245-257.
- 38. National Center for Complementary and Integrative Health. *Are You Considering a Complementary Health Approach?* 2016 [cited 2021 30 June]; Available from: https://www.nccih.nih.gov/health/are-you-considering-a-complementary-health-approach.
- 39. von Ammon, K., et al., Complementary and alternative medicine provision in Europe–first results approaching reality in an unclear field of practices. Complementary Medicine Research, 2012. 19(Suppl. 2): p. 37-43.
- 40. World Naturopathic Federation, *World Naturopathic Federation Report*. 2015, World Naturopathic Federation: Ontario, Canada.
- 41. Ooi, S.L., L. McLean, and S.C. Pak, *Naturopathy in Australia: Where are we now? Where are we heading?* Complementary therapies in clinical practice, 2018. **33**: p. 27-35.
- 42. Myers, S. and V. Vigar, The State of the Evidence for Whole-System Multi-Modality Naturopathic Medicine: A Systematic Scoping Review. The Journal of Alternative & Complementary Medicine, 2019. **25**(2).
- 43. Steel, A., et al., Generational differences in complementary medicine use in young Australian women: Repeated cross-sectional dataset analysis from the Australian longitudinal study on women's health. Complementary therapies in medicine, 2019. **43**: p. 66-72.

AUTHOR CONTRIBUTIONS

AS devised the project, the main conceptual idea and drafted the review protocol. All authors reviewed and edited the protocol prior to registration. Literature searching, removal of duplicates and filtering of citations by title and abstract was undertaken by AM. Full text retrieval and assessment of articles against eligibility criteria was undertaken by AM and AS. Data extraction was completed by JHar. STROBE assessment was completed by CVV, JS and AS. Risk of bias assessment was completed by JG, JHaw and AS. Meta-analysis was completed by JG, KC and HC. The method section of the manuscript was drafted by HC, AS, JS and JHaw. The results were drafted by AS and HC. The discussion was drafted by JHar, JW, JA and BL. The introduction was drafted by RR, ML, and RB. All authors reviewed and edited the full draft of the manuscript prior to submission.

COMPETING INTERESTS

The authors have no competing interests to declare.

FUNDING

This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors.

Table 1. Philosophical principles of naturopathy [3]

- First do no harm
- Healing power of nature
- Treat the cause
- Treat the whole person
- Disease prevention and health promotion
- Naturopathic practitioner as teacher

Table 2: Example search terms applied to database searches

- 1. EXP COMPLEMENTARY THERAPIES/
- 2.((ALTERNATIVE OR COMPLEMENTARY OR INTEGRATIVE) ADJ (MEDICINE OR THERAPY OR THERAPIES)).TW,KW. 3. NATUROPATHY/
- 4. NATUROPAT\$.AF.
- 5. HEILPRAKTIKER.AF.
- 6. 1 OR 2 OR 3 OR 4 OR 5
- 7. COHORT STUDIES/ OR LONGITUDINAL STUDIES/ OR FOLLOW-UP STUDIES/ OR PROSPECTIVE STUDIES/ OR COHORT.TI,AB. OR LONGITUDINAL.TI,AB. OR PROSPECTIVE.TI,AB. OR RETROSPECTIVE.TI,AB.
- 8. CROSS-SECTIONAL STUDIES/ OR PREVALENCE/ OR (CROSS-SECTIONAL OR PREVALENCE OR TRANSVERSAL).TI,AB,KW.
- 9. (OBSERVATIONAL ADJ (STUDY OR STUDIES)).TW.
- 10. SURVEY\$.TW.
- 11. 7 OR 8 OR 9 OR 10
- 12.6 AND 11

Figure 1: Flow chart representing article selection method in line with PRISMA protocol

ATTACHED

TABLE 3: SUMMARY INFORMATION OF INCLUDED STUDIES REPORTING PREVALENCE OF USE OF NATUROPATHY IN THE PREVIOUS 12 MONTHS

WHO Region	Country (WHO Region)	Author	Economic status	Design (measure)	Year data collected	Population	Naturopathy descriptor	Setting (e.g. urban, rural)	N	Duration of exposure	Overall use (%)
European	England	Hunt et a∣(2010)	Nationally representative	National Cohort (survey)	2005	General population	Naturopathy	Both	7630	Previous 12 months	2%*
	Switzerland	Klein et al. (2015)	Nationally representative	National Cohort (survey)	2007, 2012	General population	Naturopathy	Both	2007: 14,432 2012: 18,357	Previous 12 months	2007: n=1185; 7.7% 2012: n=1597; 7.7%
Eastern Mediterranean	Israel	Shmueli, et al (2010)	Subjective economic status 'very good' or 'good' range from M=0,49 to M=0.58	cross- sectional (su rvey)	1993, 2000, 2007	General population	Natu ropathy	Urban	1993: 2003 2000: 2505 2007: 752	Previous 12 months	1993: n=400; 20% 2000: n=425; 17% 2007: n=135; 18%
Region of the Americas	Canada	Esmail (2017)	Evenly distributed (<\$20 000 - >\$79 999)	Cross- sectional (structured telephone interviews)	1997, 2006, 2016	General population	Natu ropathy	National	1997: 1500 2006: 2000 2016: 2000	Previous 12 months	1997: n=45; 3% 2006: n=80; 4% 2016: N=100; 5%
	USA	Su and Li (2011)	Nationally representative	cross- sectional survey (survey)	2002, 2007	General population	Natu ropathy	National	2002: 30267 2007: 20769	Previous 12 months	2002: n=76; 0.25% 2007: n=71; 0.34%
		Clarke et al (2015)	Nationally representative	Cross- sectional (survey)	2012	General population	Naturopathy	National	38280	Previous 12 months	n=153; 0.4%
Western Pacific	Australia	McIntyre et al. (2019)	Manageability on hou sehold income; impossible, difficult all/some of time (58.6%), not too bad / easy (41.4%)	National Cross- sectional (survey)	2017	General population	Naturopathy and western herbal medicine	Both Urban: 72.6% Inner regional: 18.7% Outer reg/remote: 8.7%	2019	Previous 12 months	n=126; 6.2%

^{*} Estimated figure based on interpretation of the chart included in the article.

TABLE 4: SUMMARY INFORMATION OF INCLUDED STUDIES REPORTING PREVALENCE OF USE OF NATUROPATHY OVER OTHER TIME PERIODS

WHO Region	Country (WHO Region)	Author	Economic status	Design (measure)	Year data collected	Population	Naturopathy descriptor	Setting (e.g. urban, rural)	N	Duration of exposure	Overall use (%)
Region of the Americas	Canada	Esmail (2017)	Evenly distributed (<\$20 000 - >\$79 999)	Cross- sectional survey	1997, 2006, 2016	General population	Naturopathy	Both	1500 (1997); 2000 (2006); 2000 (2016)	Ever used	1997: 6% 2006: 9% 2016: 11%
South- East Asian	India	Srinivasan and Raji Sugumar (2017)	Diversity of occupation, social group, education, and religion	Cross- sectional (survey)	2011-2012	Households in the general population	Naturopathy and yoga	Both	Total: 65507 Urban: 26996 Rural: 38511	Not specified	Total: n=6616 (10%) Urban: n=3227 (12%) Rural: n=2607 (7%)

TABLE 5: ASSESSMENT OF RISK OF BIAS AND REPORTING QUALITY FOR INCLUDED STUDIES


	Manuscript									
Criteria	Hunt et al (2010)	Klein et al (2015)	Shmueli et al (2010)	Esmail (2017)	Su and Li (2011)	Clarke et al (2015)	McIntyre et al (2019)	Srinivasan and Raji Sugumar (2017)		
Risk of Bias										
1 – representativeness of target population	Υ	Υ	Υ	Υ	Υ	Υ	Υ	Υ		
2 – representativeness of sample population	Υ	Υ	Υ	Υ	Υ	Υ	Υ	Υ		
3 – random selection or census	Υ	Υ	Υ	Υ	Υ	Υ	N	Υ		
4 – non-response bias minimal	Υ	Υ	N	Υ	Υ	Υ	N	Υ		
5 – data direct from participants	Υ	Υ	Υ	Υ	Υ	Υ	Υ	Υ		
6 – acceptable case definition	Υ	Υ	Υ	Υ	Υ	Υ	Υ	N		
7 – reliability and validity of instrument	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A		
8 – same mode of data for all subjects	Υ	Υ	Υ	Υ	Υ	Υ	Υ	Υ		
9 – appropriate length of shortest prevalence period	Υ	Υ	Υ	Υ	Υ	Υ	Υ	N		
10 – numerator and denominator appropriate	N	N	N	N	N	N	Υ	Υ		
11 - Summary	Low	Low	Low	Low	Low	Low	Low	Low		
Reporting Quality										
Title and abstract										
1a – Title	Υ	Υ	N	N	N	N	N	Υ		
1b - Abstract	Υ	Υ	Υ	Υ	N	N	Υ	N		
Introduction										
2 - Background/rationale	Υ	Υ	Υ	Υ	Υ	Υ	Υ	Υ		
3 - Objectives	Υ	Υ	Υ	Υ	Υ	Υ	Υ	Υ		
Methods										
4 - Study design	Υ	Υ	Υ	Υ	Υ	Υ	Υ	Υ		
5 - Setting	Υ	Υ	Υ	Υ	Υ	Υ	Υ	Υ		
6 - Participants	Υ	Υ	Υ	Υ	Υ	Υ	Υ	Υ		
7 - Variables	Υ	Υ	Υ	N	N	Υ	Υ	N		
8 - Data sources/measurement	Υ	Υ	Υ	N	Υ	Υ	Υ	Υ		
9 - Bias	Υ	Υ	Υ	Υ	Υ	Υ	Υ	N		
10 - Study size	Υ	Υ	Υ	Υ	N	N	Υ	Υ		
11 - Quantitative variables	Υ	Υ	Υ	N	N	Υ	Υ	N		
12a – All statistical methods	Υ	Υ	N	N	Υ	Υ	Υ	N		
12b – Subgroups and interactions	N/A	N/A	N/A	Υ	Υ	Υ	Υ	Υ		
12c – Missing data	N	Υ	N	N	N	N	N	N		

12d – Analysis accounting for sampling	N/A	N/A	Υ	N	Υ	Υ	Υ	N
12e – Any sensitivity analysis	N/A							
Results								
13a – Numbers of participants	Υ	Υ	Υ	Υ	N	N	Υ	N
13b – Reasons for nonparticipation	Ν	N	Ν	N	N	N	N	N
13 c – flow diagram	Ν	N	Ν	N	N	N	N	N
14a – Characteristics of study participants	Υ	Υ	Ν	Υ	N	Υ	Υ	Υ
14b – Participants with missing data	N	N	N	N	N	N	N	N
15 - Outcome data	N	Υ	Y	Υ	Υ	Υ	Υ	Υ
16a – Unadjusted and applicable adjusted estimates	Υ	Υ	Υ	Υ	Υ	Υ	Υ	Υ
16b – Report category boundaries	?	Υ	N/A	N	N/A	N/A	Υ	N/A
16c –Estimates of absolute risk	N/A							
17 - Other analyses	N/A	N/A	N/A	Υ	Υ	Υ	Υ	Υ
Discussion								
18 - Key results	Υ	Υ	Υ	Y	Υ	Υ	Υ	N
19 - Limitations	Υ	Υ	Υ	N	N	N	Υ	N
20 - Interpretation	Υ	Υ	Υ	N	Υ	Υ	Υ	N
21 - Generalisability	Υ	Υ	Υ	Υ	Υ	Υ	Υ	N
Other information								
22 - Funding	Υ	Υ	Υ	Υ	N	N	Υ	Υ

Figure 2: 12-month prevalence of naturopathy use in different countries.

Figure 3: 12-month prevalence of naturopathy use in different WHO world regions.

				2-month prevalence	12-month prevalence
Study or Subgroup	12-month prevalence	SE	Weight	IV, Random, 95% CI	IV. Random, 95% CI
1.2.1 European	and the second s			**************************************	334394,000,000,000,000
Hunt 2010	0.02005242	0.00162114	33.4%	0.02 [0.02, 0.02]	
K3ein 2007	0.0821092	0.00238524	33.3%	0.08 (0.08, 0.09)	
Klein 2012	0.08699679	0.00217696	33.3%	0.09 [0.08, 0.09]	
Subtotal (95% CI)			100.0%	0.06 [0.02, 0.11]	
Heterogeneity: Tau*	0.00; Chi* = 805.79, df =	2 (P < 0.0000	1); P= 100	1%	
Test for overall effect	Z = 2.67 (P = 0.008)				
1.2.2 Eastern Medite	rranean				
Shmueli 1993	0.01198203	0.00244582	42.6%	0.01 [0.01, 0.02]	
Shmueli 2000	0.01676647	0.00258712	40.7%	0.02 [0.01, 0.02]	
Shmueli 2007	0.02260638	0.00548285	16.6%	0.02 [0.01, 0.03]	-
Subtotal (95% CI)			100.0%	0.02 [0.01, 0.02]	•
Heterogeneity. Tau* =	0.00; Chi* = 3.91, df = 2	$(P = 0.14), I^2 =$	49%		
Test for overall effect	Z = 6.13 (P < 0.00001)				
1.2.3 Region of the A	mericas				
Clarke 2015	0.0039969	0.0003231	24.9%	0.00 (0.00, 0.00)	
Esmail 1997	0.03	0.0044721	8.9%	0.03 [0.02, 0.04]	-
Esmail 2006	0.04	0.0044721	8.9%	0.04 [0.03, 0.05]	-
Esmail 2016	0.05	0.005	7.7%	0.05 [0.04, 0.06]	-
Su 2002	0.00251099	0.00028803	24.9%	0.00 [0.00, 0.00]	
Su 2007	0.00341856	0.00040571	24.8%	0.00 [0.00, 0.00]	
Subtotal (95% CI)			100.0%	0.01 [0.01, 0.02]	•
Heterogeneity, Tau*	0.00; Chi* = 202.16, df =	5 (P < 0.0000	1), P= 989	6	
Test for overall effect	Z = 7.55 (P < 0.00001)				
1.2.4 Western Pacifi	c				
McIntyre 2019 Subtotal (95% CI)	0.06240713	0.00555967	100.0%	0.06 [0.05, 0.07] 0.06 [0.05, 0.07]	
Heterogeneity Not as	oplicable			SEPTEMBER DESIGNATION	35.0
	Z=11.22 (P < 0.00001)				
					-0.1 -0.05 0 0.05 0.1



	42	- 22		12-month prevalence	12-month prevalence
Study or Subgroup 1.1.1 Australia	12-month prevalence	SE	Weight	IV, Random, 95% CI	IV, Random, 95% CI
McIntyre 2019	0.06340743	0.00555967	100.0%	0.06 (0.05, 0.07)	
Subtotal (95% CI)	0.00240713	0.00555967	100.0%	0.06 [0.05, 0.07]	
Heterogeneity: Not as	oplicable				
	Z = 11.22 (P < 0.00001)				
1.1.2 Canada					
Esmail 1997	0.03	0.0044721	33.9%	0.03 [0.02, 0.04]	•
Esmail 2006	0.04	0.0044721	33.9%	0.04 [0.03, 0.05]	
Esmail 2016	0.05	0.005	32.2%	0.05 [0.04, 0.06]	_
Subtotal (95% CI)			100.0%	0.04 [0.03, 0.05]	•
	0.00; Chi*= 8.93, df= 2 Z= 7.03 (P < 0.00001)	(P = 0.01); P=	78%		
1.1.3 England					_
Hunt 2010	0.02005242	0.00162114	100.0%	0.02 [0.02, 0.02]	
Subtotal (95% CI)			100.0%	0.02 [0.02, 0.02]	•
Heterogeneity: Not ag					
Test for overall effect	Z = 12.37 (P < 0.00001)				
1.1.4 Israel					
Shmueli 1993		0.00244582	42.6%	0.01 [0.01, 0.02]	•
Shmueli 2000	1,500,000,000,000	0.00258712	40.7%	0.02 [0.01, 0.02]	
Shmueli 2007	0.02260638	0.00548285	16.6%	0.02 (0.01, 0.03)	
Subtotal (95% CI)			100.0%	0.02 [0.01, 0.02]	0.950
	0.00; Chi ² = 3.91, df = 2 Z = 6.13 (P < 0.00001)	(P = 0.14), P=	49%		
1.1.5 Switzerland					
Klein 2007	0.0821092	0.00238524	48.0%	0.08 (0.08, 0.09)	
K3ein 2012	0.08699679	0.00217696	52.0%	0.09 [0.08, 0.09]	
Subtotal (95% CI)		Service and the	100.0%	[60.0 '80.0] 80.0	•
	0.00; Chi* = 2.29, df = 1 Z = 34.67 (P < 0.00001)	(P = 0.13); P=	56%		
1.1.6 USA					
Clarke 2015	0.0039969	0.0003231	33.9%	0.00 [0.00, 0.00]	
Su 2002	0.00251099	0.00028803	35.0%	0.00 (0.00, 0.00)	
Su 2007	0.00341856	0.00040571	31.1%	0.00 [0.00, 0.00]	
Subtotal (95% CI)			100.0%	[00.0 ,00.0]	
	0.00; Chi ² = 12.08, df = 2 Z = 6.92 (P < 0.00001)	2 (P = 0.002); I	*= 83%		
				-0	1 -0.05 0 0.05 0.1